FY2025 EPS Estimates for BrainsWay Reduced by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of BrainsWay in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.18 for the year, down from their prior estimate of $0.32. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share.

BrainsWay Price Performance

Shares of NASDAQ BWAY opened at $10.21 on Monday. The stock has a market capitalization of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. BrainsWay has a one year low of $4.61 and a one year high of $11.79. The firm’s 50 day simple moving average is $10.26 and its two-hundred day simple moving average is $9.63.

Hedge Funds Weigh In On BrainsWay

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after buying an additional 11,221 shares during the period. Rhumbline Advisers grew its position in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the last quarter. ARK Investment Management LLC purchased a new position in BrainsWay in the 4th quarter worth approximately $1,656,000. Sei Investments Co. bought a new stake in BrainsWay in the fourth quarter valued at approximately $149,000. Finally, Phoenix Financial Ltd. boosted its stake in shares of BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock valued at $4,552,000 after purchasing an additional 242,366 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.